For resources and updates from the Office of Research Integrity Assurance related to the Coronavirus, visit: https://researchintegrity.gatech.edu/coronavirus.
The Institutional Biosafety Committee (IBC) is charged with reviewing all registrations for research, teaching, and training that involve the use of recombinant DNA and synthetic nucleic acid molecules (rDNA) at Georgia Tech. The committee also ensures that proposed activities comply with all federal regulations and policies governing these activities.
The IBC is constituted in accordance with the National Institutes of Health Guidelines for Research involving Recombinant or Synthetic Nucleic Acid Molecules. Members are appointed by the Georgia Tech Executive Vice President for Research. The IBC generally meets monthly and as needed to review registrations proposing use of rDNA.
The Office of Research Integrity Assurance (ORIA) provides administrative support to the committee and is responsible for maintaining Georgia Tech’s registration with the National Institutes of Health’s Office of Science Policy.
All activities involving rDNA must be approved in advance of their initiation.
Prerequisites for Approval
The following prerequisites are required for IBC Protocol Approval
- All individuals listed on the application (including the PI) must be up-to-date with all required training.
- All individuals listed on the application (including the PI) must be enrolled in the Biosafety Occupational Health Program.
- A successful biosafety lab inspection must have occurred within the past year.
- PI must submit a current Biological Hygiene Plan along with the registration.